Market size

A Competitive Pricing Model

Predicted ASP: $6,000

At EndoShunt, the company adopts a value-based pricing strategy, carefully crafting its positioning in the market. Priced at $6000 per unit when sold directly to hospitals, EndoShunt stands competitively among other devices in the endovascular hemorrhage control category, with notable products like ER-REBOA™ PLUS by Prytime Medical priced at approximately $4500 per unit. The company takes pride in the substantial value EndoShunt adds to hospitals, significantly improving patient outcomes, increasing survival rates, and enhancing the likelihood of patient admissions and follow-on care. Furthermore, EndoShunt strategically sets its price below the threshold that triggers additional approval requirements for medical device purchases in hospitals, ensuring a streamlined procurement process. The commitment to value-based pricing underscores the company’s dedication to making a positive impact on patient care and operational efficiency, reinforcing EndoShunt’s position as an essential and life-saving endovascular device.

Beach Head Market

EndoShunt’s beachhead market comprises the trauma setting, specifically targeting patients with injuries to blood vessels at the abdominal, lower back, and pelvis levels (ICD-10 S35), as well as injuries to intra-abdominal organs (ICD-10 S36). Leveraging data from the Trauma Quality Improvement Program (TQIP), there were 68.07 thousand trauma activations at level one trauma centers in 2019, indicating a need for EndoShunt. With a value-based pricing strategy, EndoShunt’s initial market size in trauma is estimated to be $396 million, making it a cost-effective solution compared to alternative treatments. As the company explores further granularity in the diagnostic codes and validates the data, EndoShunt remains committed to delivering innovative solutions to improve patient outcomes in the trauma care landscape.

TAM

EndoShunt’s current market size in trauma care, estimated at $396 million based on 68.07 thousand trauma activations at level one trauma centers in the US in 2019, is just the beginning. As the device diversifies into additional medical fields, such as OBGYN, transplant, and oncology, the addressable market could potentially grow exponentially. For instance, the global oncology market was valued at $150.3 billion in 2020, while the global transplant market reached $27.9 billion in the same year. By capturing even a fraction of these markets, EndoShunt’s revenue potential could be substantial. Additionally, its adaptability for use by paramedics and military units in critical field settings opens new possibilities, with military spending on medical devices estimated to be in the billions annually. Furthermore, venturing into international markets, where the global medical device market is projected to reach $612.7 billion by 2027, EndoShunt’s growth trajectory holds immense promise. With the right strategies and value-driven approach, EndoShunt has the potential to become a dominant player in the endovascular shunting industry, revolutionizing patient care and yielding significant returns for investors.

Provisional Tips MarketSize

This document summarizes the current approach to market sizing using data from TQIP, and the provisional results.